
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a leading player in the regenerative medicine market, with a diverse portfolio of products that address a range of chronic wounds and musculoskeletal injuries. While recent reimbursement changes have been a headwind for the company, we believe Organogenesis will emerge as a market leader as smaller players exit the space due to unfavorable economics. Additionally, the company's promising new product, ReNu, could provide significant upside once it receives FDA approval and reimbursement is settled. Overall, we expect Organogenesis to continue its strong growth trajectory in the long term.
Bears say
Organogenesis Holdings is facing significant challenges in the near future, with a decline in revenue and profitability expected in 2026 due to confusion in the provider level leading to decreased sales and limited visibility in their business. The company operates in a single segment, with a diverse portfolio of regenerative medicine products, but faces competition in the wound care sector and uncertainty surrounding their new product ReNu. Additionally, changes in reimbursement policies and regulations from CMS could have a significant impact on the company's financial performance. However, the company's strong product offering and potential for growth in the future, particularly with the launch of ReNu, could mitigate some of these challenges.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares